Uninterrupted Continuation of VV-ECMO Without Anticoagulation for 44 Days in COVID-19 ARDS: A Precarious Quandary

Venovenous extracorporeal membrane oxygenation (VV-ECMO) has become a mainstay treatment modality for a select patient population who do not respond to conventional medical therapy suffering from severe acute respiratory distress syndrome (ARDS) due to COVID-19. This therapy necessitates the utiliza...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sankalp P., Solomon, Brian J., Pascotto, Robert D., D'Orazio, Stephen E., Navas, Elsy V., Cubeddu, Robert J., Cudemus, Gaston A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994674/
https://www.ncbi.nlm.nih.gov/pubmed/35545457
http://dx.doi.org/10.1053/j.jvca.2022.04.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994674/
https://www.ncbi.nlm.nih.gov/pubmed/35545457
http://dx.doi.org/10.1053/j.jvca.2022.04.006

Ejemplares similares